Tralokinumab
Based on 2 publication(s) in Google Scholar
Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis.
For research use only. We do not sell to patients.
- Purity : 99.12%
- CAS No.: 1044515-88-9
- Molecular Weight:144.14 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Tralokinumab
More-
Cell Imaging/Staining
-
IF
All Caspase Isoforms
More
Biological Activity
Description
Isotype
Human IgG4 lambda
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
IL-13 |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female C.B-17-scid-beige (C.B-17SCID/bg) mice received single-cell preparations of IPF and normal fibroblasts via tail vein injection[2]
-
Dosage:3 mg/kg
-
Administration:Intraperitoneal injection; once every other day; from day 35 to day 63
-
Result:Blocked aberrant lung remodeling, promoted lung repair and restored epithelial integrity.
Significantly decreased fibrotic alterations.
Reduced serum CC16 (a marker of epithelial injury) and reduced BAL caspase 3 activity.
Enhanced the expression of epithelial-associated genes, including E-cadherin and all of the surfactants.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 lambda
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Tralokinumab (HY-P99053) neutralizes Recombinant Human IL-13 (HY-P70568) induced proliferation in the TF-1 human erythroleukemic cell line. The Neutralization Dose (ND50) for this effect is 0.6630 μg/mL in the presence of 10 ng/mL Recombinant Human IL-13.
Chemical Information
-
CAS No. 1044515-88-9
-
Appearance Liquid
-
Molecular Weight 144.14 kDa
-
Color Colorless to light yellow
-
SMILES
[Tralokinumab]
-
Synonyms
CAT354
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
ACS Nano
Combining Microfluidic Assessment with Encoded Hydrogel Microparticle-Based Immunoassay for Anti-Interleukin Drug Repurposing of Pulmonary Fibrosis Therapy. [Abstract]2025 Sep 16;19(36):32361-32373. PMID: 40903905
Tralokinumab purchased from MedChemExpress. Usage Cited in: ACS Nano. 2025 Sep 16;19(36):32361-32373. [Abstract]
Representative images of fibrosis-induced spheroids subjected to microfluidic deformation analysis, comparing untreated control, antifibrotic drug NTD, and anti-interleukin drugs TCZ, STX, DUP, and TRA. Mab (5 μg/mL, 1 d) were added, Scale bars indicate 100 μm.
Tralokinumab purchased from MedChemExpress. Usage Cited in: ACS Nano. 2025 Sep 16;19(36):32361-32373. [Abstract]
Confocal fluorescence images showing the expression of collagen-1 and α-SMA in spheroids treated with NTD, TCZ, STX, DUP, and TRA. Mab (5 μg/mL, 1 d) were added, Scale bars indicate 100 μm.
-
bioRxiv
Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors. [Abstract]2025 Jan 25:2025.01.24.631210. PMID: 39896575
Protocols
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
TPA/Croton Oil Ear Edema and Dermatitis
The TPA (12-O-tetradecanoylphorbol-13-acetate) and croton oil-induced mouse ear edema model is a well-established acute cutaneous inflammation system used to evaluate topical anti-inflammatory activity by measuring edema formation, neutrophil infiltration, vascular permeability, and cytokine-mediated skin responses in vivo. The inflammatory response is triggered by topical application of phorbol esters (TPA) or croton oil constituents, leading to rapid activation of protein kinase C signaling, leukocyte recruitment, and increased vascular permeability, which can be quantified by ear thickness, weight, dye extravasation, and biochemical markers such as myeloperoxidase (MPO) activity and pro-inflammatory mediators in ear tissue homogenates. This model is widely used for screening anti-inflammatory agents, where reductions in edema and inflammatory biomarkers reflect suppression of acute dermal inflammation and immune cell infiltration. Histological evaluation typically confirms epidermal
-
Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
Masson’s Trichrome (collagen/trichrome staining) is a histological technique that differentially stains tissue compartments using sequential acidic dyes to distinguish collagen from muscle and cytoplasmic components based on dye affinity and tissue permeability differences, enabling visualization of fibrosis and connective tissue architecture in histological sections. The classical formulation typically uses Weigert's iron hematoxylin for nuclear staining, Biebrich scarlet-acid fuchsin for cytoplasm and muscle, and aniline blue (or light green variants) for collagen, producing a characteristic blue/green collagen signal contrasted against red cytoplasm and dark nuclei. The staining principle relies on selective displacement of smaller dye molecules by larger anionic dyes in collagen-rich regions under controlled acidified conditions, which enhances collagen-specific dye retention. This property makes the method widely used for fibrosis assessment in organs such as heart, liver, lung, a
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. A Wollenberg, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021 Mar;184(3):437-449. [Content Brief]
[2]. Murray LA, et al. Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. Am J Respir Cell Mol Biol. 2014 May;50(5):985-94. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)